SAN DIEGO / Nov 04, 2025 / Business Wire / Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
Guggenheim's 2nd Annual Healthcare Innovation Conference
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET
Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025
TD Cowen Immunology & Inflammation Summit
Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET
Jefferies Global Healthcare Conference
Presenting on Tuesday, November 18, 2025, at 3:00 p.m. GMT (10:00 a.m. ET)
8th Annual Evercore Healthcare Conference
Presenting on Tuesday, December 2, 2025, at 10:50 a.m. ET
Piper Sandler 37th Annual Healthcare Conference
Wednesday, December 3, 2025
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
| Last Trade: | US$32.34 |
| Daily Change: | -0.96 -2.88 |
| Daily Volume: | 2,802,322 |
| Market Cap: | US$2.890B |
October 30, 2025 October 17, 2025 September 10, 2025 September 03, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load